Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Analytical Characterization

Hovione advanced characterization capabilities of inhalation and nasal products is crucial to determine their safety and efficacy.

Page
Read more

Drug delivery platforms

Hovione has unique capabilities and expertise in solubility enhancement, lung delivery, modified release and taste-masking applications.

Page
Read more

What we do

Hovione is a Contract Development and Manufacturing Company dedicated to helping Pharmaceutical Customers bring new and off-patent drugs to market.

Page
Read more